All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Join our
Treating classical Hodgkin lymphoma: Spotlight on targeted therapies
with Gilles Salles, Paul Bröckelmann, and Ann S. LaCasce
Saturday, November 2, 2024
8:50-9:50 CET
This independent educational activity is sponsored by Takeda. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?
During the 25th Congress of the European Hematology Association (EHA), the MDS Hub spoke to Amer Zeidan, Yale School of Medicine, New Haven, US. We asked: What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?
What does the STIMULUS program tell us about combination therapy with MBG453 in MDS?
The STIMULUS program represents a number of clinical trials that are evaluating the anti-TIM-3 checkpoint inhibitor, MBG453, for the treatment of myeloid malignancies. Alternative immune checkpoint inhibitors have demonstrated mixed results, and therefore the TIM-3 pathway is being investigated for therapeutic intervention.
In early phase clinical trials, MBG453 combination regimens exhibited promising clinical activity, prompting the further studies that now comprise the STIMULUS program.
Related articles
Newsletter
Subscribe to get the best content related to MDS delivered to your inbox